Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Shares Gap Up – Should You Buy?
by Michael Walen · The Markets DailySwedish Orphan Biovitrum (OTCMKTS:BIOVF – Get Free Report)’s share price gapped up before the market opened on Wednesday. The stock had previously closed at $42.80, but opened at $46.00. Swedish Orphan Biovitrum shares last traded at $46.00, with a volume of 102 shares traded.
Wall Street Analysts Forecast Growth
BIOVF has been the topic of several recent analyst reports. Pareto Securities lowered Swedish Orphan Biovitrum to a “hold” rating in a report on Monday, June 29th. Barclays reaffirmed an “overweight” rating on shares of Swedish Orphan Biovitrum in a report on Friday, July 3rd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Swedish Orphan Biovitrum in a report on Tuesday, July 21st. Four equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy”.
Read Our Latest Stock Report on BIOVF
Swedish Orphan Biovitrum Stock Up 7.5%
The firm has a market cap of $16.38 billion, a PE ratio of 102.22 and a beta of 0.47. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.55 and a current ratio of 0.88. The firm’s 50-day moving average price is $46.45 and its two-hundred day moving average price is $46.37.
Swedish Orphan Biovitrum Company Profile
Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Sweden-based biopharmaceutical company focused on developing, manufacturing and commercializing medicines for rare diseases. Its principal therapeutic areas include hematology, immunology and specialty care, with an emphasis on conditions that often have limited treatment options.
Sobi’s portfolio includes therapies for rare blood disorders, immune-mediated diseases and other specialized conditions. Its products include Doptelet (avatrombopag), Gamifant (emapalumab), Aspaveli (pegcetacoplan), Alprolix (eftrenonacog alfa) and Elocta (efmoroctocog alfa), along with additional medicines marketed through collaboration and licensing arrangements.